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Thirty-five years ago it was observed for 
the first time that sodium butyrate inhib-
its tumor cell growth by inducing histone 
acetylation.1,2 Twenty years later the first 
histone deacetylase (HDAC1) was cloned3 
and it was understood that the anti-
cancer effect of butyrate was due to its 
ability to inhibit HDACs’ activity. Since 
then, a massive amount of studies have 
investigated the therapeutic potential of 
the various HDAC inhibitors (HDACi) 
on different tumors, providing evidence 
that these compounds may be considered 
effective tools against several cancers. 
Currently, only one HDAC inhibitor, the 
suberoylanilide hydroxamic acid (SAHA 
or Vorinostat), has been approved by FDA 
for the treatment of cutaneous T cell lym-
phoma, and other inhibitors have entered 
clinical trias in other malignancies.4
One potential limitation to the use 
of HDAC inhibitors is that they have a 
broad spectrum of action, which results 
in the onset of undesirable side effects 
at higher doses. For this reason, a lot of 
effort has been made to understand the 
molecular basis of HDACi action, in order 
to develop therapeutic strategies aimed at 
targeting the selective epigenetic altera-
tions involved in each tumor. To this end, 
several studies have been conducted to 
characterize the acetylated substrates fol-
lowing HDACi administration. It is now 
widely accepted that, in addition to his-
tones, the originally identified substrates, 
inhibition of HDACs also results in acety-
lation of non-histone proteins.5
The anti cancer effect of the HADC 
inhibitors has been largely attributed to 
their ability to modulate the acetylation 
status of chromatin, thereby inducing or 
repressing the expression of genes involved 
in cell cycle, apoptosis, angiogenesis and 
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immune response. Alternatively, HDAC 
inhibitors have been shown to exert their 
anti cancer effect by an acetylation-medi-
ated enhancement of transcription factors 
promoting cell cycle arrest or apoptosis, 
such as p53, p73, E2F1, pRb and NFκB.6 
Recently, it has been shown an alterna-
tive and unexpected mechanism by which 
HDAC inhibition promotes acetylation of 
an oncogene, thereby preventing its tran-
scriptional activation.7 This inhibitory 
event counteracts the growth of medul-
loblastoma, a malignant brain tumor 
of the childhood that often arises from 
inappropriate activation of the Hedgehog 
signaling pathway.8 Starting from the 
observation that loss of class I HDAC 
disrupts the transcriptional response to 
Hh activation, HDAC1 and 2 are shown 
to bind and deacetylate the oncogenic 
transcription factor Gli1, the most potent 
effector of the Hh pathway. HDAC-
dependent deacetylation causes enhanced 
Gli1 transcriptional activity, whereas ecto-
pic expression of HAT/p300 has an oppo-
site inhibitory effect.
Gli1 is acetylated at a single lysine 
(K518) that is conserved in Gli2 but not in 
Gli3 and K518R mutation, which mimics 
a status of constitutive deacetylation and 
confers increased transcriptional activ-
ity. Therefore, acetylation functions as an 
inhibitory switch that negatively affects 
the transcriptional activity of Gli1 and 
Gli2. Mechanistically, it is unclear how 
Gli activity is inhibited by acetylation. 
A change in Gli DNA binding affinity, 
intracellular localization or turnover rate 
has been ruled out and it seems plausible 
that acetylation affects Gli transactiva-
tion potential, an effect that could be due 
to changes in binding affinity for tran-
scriptional co-activators or co-repressors. 
Unfortunately, the current knowledge of 
the mechanisms leading to transcriptional 
activation of Gli-target genes are only 
poorly understood and a better knowl-
edge of the proteins that mediate the 
Gli-dependent transcriptional process is 
needed to properly address this issue.
Gli acetylation is finely regulated by two 
opposite mechanisms. One mechanism is 
triggered by activation of the Hh pathway 
and leads to increased HDAC1 mRNA 
and protein levels, and consequent Gli1 
deacetylation and Hh-target gene activa-
tion. Since Gli1 activates its own expres-
sion, this mechanism turns on a positive 
feedback loop between Gli deacetylation 
and HDAC1/Gli1 upregulation. The sec-
ond, inhibitory mechanism is regulated 
by the tumor suppressor RENKCTD11, a 
protein that was initially identified as a 
Hedgehog inhibitor, encoded by a gene 
located in chromosome 17p, deleted in 
most of medulloblastomas.9 REN turns 
off the positive Gli1/HDAC1 feedback 
loop by downregulating HDAC1 levels. 
Indeed, REN functions as an endogenous 
HDAC inhibitor that binds Cul3, a com-
ponent of the SCF-like E3 ubiquitin ligase 
complex, and targets HDAC1 to ubiq-
uitination and subsequent proteasomal 
degradation. Consistent with its role as 
a HDAC inhibitor, REN promotes Gli1 
acetylation, thereby inhibiting the expres-
sion of Hh-target genes. Therefore, activa-
tion of Hedgehog and REN seem to work 
in an opposite and coordinated fashion, by 
regulating HDAC1 levels and, ultimately, 
Gli1 acetylation.
What are the consequences of an 
imbalance of this finely orchestrated equi-
librium? The prediction is that any per-
turbation of the mechanisms that govern 
Gli acetylation will have an impact on cell 
2048 Cell Cycle Volume 9 Issue 11
proliferation and, eventually, may lead to 
malignant transformation. Indeed, consti-
tutively deacetylated Gli1 mutants cause 
increased cell proliferation and transfor-
mation, and increased HDAC1 levels and 
REN downregulation are observed in 
Hh-dependent medulloblastoma.
Thus, acetylation of Gli1 represents a 
finely-tuned transcriptional checkpoint in 
neuronal cells and is the first example of 
an oncogene whose activation is inhibited 
by its own acetylation. This mechanism 
works in concert with the activating acet-
ylation of oncosuppressors since they all 
share a common final outcome: the inhi-
bition of tumor cell growth. As such, Gli1 
acetylation may be considered a novel and 
promising new target for pharmacological 
screenings aimed at the identification of 
novel drugs to treat medulloblastoma and 
other Hh-dependent tumors.
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